期刊文献+

Impact of hypoglycemic agents on myocardial ischemic preconditioning 被引量:4

Impact of hypoglycemic agents on myocardial ischemic preconditioning
下载PDF
导出
摘要 Murry et al in 1986 discovered the intrinsic mechanism of profound protection called ischemic preconditioning. The complex cellular signaling cascades underlying this phenomenon remain controversial and are only partially understood. However, evidence suggests that adenosine, released during the initial ischemic insult, activates a variety of G protein-coupled agonists, such as opioids, bradykinin, and catecholamines, resulting in the activation of protein kinases, especially protein kinase C(PKC). This leads to the translocation of PKC from the cytoplasm to the sarcolemma, where it stimulates the opening of the ATP-sensitive K+ channel, which confers resistance to ischemia. It is known that a range of different hypoglycemic agents that activate the same signaling cascades at various cellular levels can interfere with protection from ischemic preconditioning. This review examines the effects of several hypoglycemic agents on myocardial ischemic preconditioning in animal studies and clinical trials. Murry et al in 1986 discovered the intrinsic mechanism of profound protection called ischemic preconditioning. The complex cellular signaling cascades underlying this phenomenon remain controversial and are only partially understood. However, evidence suggests that adenosine, released during the initial ischemic insult, activates a variety of G protein-coupled agonists, such as opioids, bradykinin, and catecholamines, resulting in the activation of protein kinases, especially protein kinase C(PKC). This leads to the translocation of PKC from the cytoplasm to the sarcolemma, where it stimulates the opening of the ATP-sensitive K+ channel, which confers resistance to ischemia. It is known that a range of different hypoglycemic agents that activate the same signaling cascades at various cellular levels can interfere with protection from ischemic preconditioning. This review examines the effects of several hypoglycemic agents on myocardial ischemic preconditioning in animal studies and clinical trials.
机构地区 MASS Study Group
出处 《World Journal of Diabetes》 SCIE CAS 2014年第3期258-266,共9页 世界糖尿病杂志(英文版)(电子版)
基金 Supported by Zerbini Foundation
关键词 ISCHEMIC PRECONDITIONING MYOCARDIAL ISCHEMIA Coronary artery disease HYPOGLYCEMIC agents Diabetes MELLITUS Ischemic preconditioning Myocardial ischemia Coronary artery disease Hypoglycemic agents Diabetes mellitus
  • 相关文献

参考文献44

  • 1朱启伟,王浩,张今尧,叶平,骆雷鸣.吡格列酮对缺氧复氧心肌细胞损伤的保护作用及对蛋白激酶C表达的影响[J].南方医科大学学报,2011,31(11):1819-1823. 被引量:8
  • 2Guo-ting Wu,Lin Wang,Jun Li,Wei-zhong Zhu.EFFECTS OF GLIBENCLAMIDE, GLIMEPIRIDE, AND GLICLAZIDE ON ISCHEMIC PRECONDITIONING IN RAT HEART[J].Chinese Medical Sciences Journal,2007,22(3):162-168. 被引量:3
  • 3Rianne Nederlof,Otto Eerbeek,Markus W Hollmann,Richard Southworth,Coert J Zuurbier.Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia‐reperfusion injury in heart[J]. Br J Pharmacol . 2014 (8)
  • 4Mohammad Sarraf,Li Lu,Shuyu Ye,Michael Reiter,Clifford Greyson,Gregory Schwartz.Thiazolidinedione Drugs Promote Onset, Alter Characteristics, and Increase Mortality of Ischemic Ventricular Fibrillation in Pigs[J]. Cardiovascular Drugs and Therapy . 2012 (3)
  • 5K. M. Pantalone,M. W. Kattan,C. Yu,B. J. Wells,S. Arrigain,A. Jain,A. Atreja,R. S. Zimmerman.Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis[J]. Diabetes, Obesity and Metabolism . 2012 (9)
  • 6A. S.Abdelmoneim,S. E.Hasenbank,J. M.Seubert,D. R.Brocks,P. E.Light,S. H.Simpson.Variations in tissue selectivity amongst insulin secretagogues: a systematic review[J]. Diabetes, Obesity and Metabolism . 2012 (2)
  • 7Goodarz Danaei,Mariel M Finucane,Yuan Lu,Gitanjali M Singh,Melanie J Cowan,Christopher J Paciorek,John K Lin,Farshad Farzadfar,Young-Ho Khang,Gretchen A Stevens,Mayuree Rao,Mohammed K Ali,Leanne M Riley,Carolyn A Robinson,Majid Ezzati.National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants[J]. The Lancet . 2011 (9785)
  • 8Lamiaa A. Ahmed,Hesham A. Salem,Amina S. Attia,Azza M. Agha.Pharmacological preconditioning with nicorandil and pioglitazone attenuates myocardial ischemia/reperfusion injury in rats[J]. European Journal of Pharmacology . 2011 (1)
  • 9Gojka Roglic,Nigel Unwin.Mortality attributable to diabetes: Estimates for the year 2010[J]. Diabetes Research and Clinical Practice . 2009 (1)
  • 10Yumei Ye,Yu Lin,Jose R. Perez-Polo,Yochai Birnbaum.Oral Glyburide, But Not Glimepiride, Blocks the Infarct-Size Limiting Effects of Pioglitazone[J]. Cardiovascular Drugs and Therapy . 2008 (6)

二级参考文献16

  • 1曹泽玲,叶平,龙超良,陈凯,李小卫,汪海.吡格列酮对缺血再灌注心肌细胞凋亡影响的实验研究[J].中华心血管病杂志,2005,33(7):648-652. 被引量:23
  • 2Helen L. Maddock,Sylvia M. Siedlecka,Derek M. Yellon.Myocardial Protection from Either Ischaemic Preconditioning or Nicorandil Is Not Blocked by Gliclazide[J].Cardiovascular Drugs and Therapy.2004(2)
  • 3F. M. Gribble,F. M. Ashcroft.Differential sensitivity of beta-cell and extrapancreatic KATP channels to gliclazide[J].Diabetologia.1999(7)
  • 4Kloner RA,Jennings RB.Consequences ofbriefischemia: stun- ning, preconditioning, and their clinical implications: part2[].Circulation.2001
  • 5Grover GJ,Garlid KD.ATP-sensitive potassium channels: a re- view of their cardioprotective pharmacology[].Journal of Molecular and Cellular Cardiology.2000
  • 6Gribble FM,Ashcroft FM.Differential sensitivity of beta-cell and extrapancreatic K (ATP) channels to gliclazide[].Diabetologia.1999
  • 7Song DK,Ashcroft FM.Glimepiride block of cloned beta-cell, cardiac and smooth muscle K (ATP) channels[].British Journal of Pharmacology.2001
  • 8Gribble FM,Tucker SJ,Seino S, et al.Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K (ATP) channels[].Diabetes.1998
  • 9Mocanu MM,Maddock HL,Baxter GF, et al.Glimepiride, a novel sulfonylurea, does not abolish myocardial protection affor- ded by either ischemic preconditioning or diazoxide[].Circulation.2001
  • 10Krentz AJ,Bailey CJ.Oral antidiabetic agents: current role in type2diabetes mellitus[].Drugs.2005

共引文献18

同被引文献8

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部